Drug Trial Radar · NCT05343455
A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)
Last checked: Nov 20, 2026Latest source record: Dec 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
330
Actual
Start
Mar 29, 2022
Primary completion
Jun 30, 2023
Study completion Jun 30, 2023
Sponsor
- Lead sponsor
- Journey Medical CorporationIndustry
- Sponsor type
- Industry
- Collaborators
- Dr. Reddy's Laboratories Limited, India
- First posted
- Apr 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 16-week, multicenter, randomized, parallel-group, double-blind, controlled study. After assessing eligibility during a screening period of up to 30 days, approximately 320 subjects at least 18 years old who are diagnosed with moderate to severe papulopustular rosacea will be randomized in a 3:3:2 ratio to DFD-29 (40 mg), Doxycycline capsules 40 mg, or Placebo once daily for 16 weeks. Of the 320 subjects, approximately 160 subjects are planned to be enrolled at 15 sites in the US, while the remaining subjects are to be enrolled at 14 sites in the EU.
Conditions
- Papulopustular Rosacea
Interventions
DFD-29Drug
DFD-29 (40 mg) extended release capsules
DoxycyclineDrug
Doxycycline 40 mg capsules
PlaceboDrug
Placebo capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Investigator's Global Assessment (IGA) Treatment Success Compared to Placebo.Time frame: Baseline to Week 16
- Change in Total Inflammatory Lesion Count Compared to Placebo.Time frame: Baseline to Week 16.
Locations
24 sites in 2 countries. Site status is shown where the registry gives one.
Clinical Trial Site 15
Santa Monica, California
Clinical Trial Site 01
Doral, Florida
Clinical Trial Site 02
Miami, Florida
Clinical Trial Site 14
Miami, Florida
Clinical Trial Site 05
Miramar, Florida
Clinical Trial Site 08
Clarksville, Indiana
Clinical Trial Site 16
Plainfield, Indiana
Clinical Trial Site 10
Louisville, Kentucky
Clinical Trial Site 11
Saint Joseph, Missouri
Clinical Trial Site 09
Cincinnati, Ohio
Clinical Trial Site 04
Dublin, Ohio
Clinical Trial Site 06
Anderson, South Carolina
Clinical Trial Site 12
Austin, Texas
Clinical Trial Site 03
Houston, Texas
Clinical Trial Site 07
Pflugerville, Texas
Clinical Trial Site 17
Bad Bentheim, Germany
Clinical Trial Site 24
Berlin, Germany
Clinical Trial Site 22
Bochum, Germany
Clinical Trial Site 20
Darmstadt, Germany
Clinical Trial Site 25
Dülmen, Germany
Clinical Trial Site 19
Hamburg, Germany
Clinical Trial Site 21
Langenau, Germany
Clinical Trial Site 23
Merzig, Germany
Clinical Trial Site 18
Wuppertal, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.